title: Transdermal estroprogestins versus transdermal estrogen plus oral dihydrogesterone replacement in menopause.
abstract: We studied 18 early (6 to 36 months) postmenopausal patients with a mean age of 51 years (47-53), who had never undergone hormone replacement therapy before and had no contraindications to hormone replacement. All cases of menopause were spontaneous. The treatment consisted in the continuous transdermal administration of 17-beta-estradiol (50 microg/daily) by skin patch to be replaced every 84 hours. The patients were further treated with a two-week progestogen administration every fortnight. This consisted of transdermal norethisterone acetate (0.25 mg/daily) combined with estradiol in the same patch in the first year, and oral dihydrogesterone (10 mg/daily) in the second year, without wash-out period. Before treatment (T0), and at the 12th (T1) and 24th (T2) month we measured the body mass index, the arterial blood pressure (AP), lipoproteins, coagulation parameters and bone metabolism parameters. The systolic pressure presented mean values (+/-SD) equal to 128.5+/-10.2 mmHg (T0), 131.1+/-7.4 mmHg (T1) and 130.4+/-7.5 mmHg (T2). Diastolic pressure values showed mean value ranging from 85.4+/-8.7 mmHg (T0) to 83.9+/-5.3 (T1) and 83.4+/-5.8 mmHg (T2). The detailed analysis of values of triglycerides, HDL cholesterol, apolipoprotein A1, apolipoprotein B and coagulation parameters at different times of therapy showed no statistically significant changes. With regard to bone metabolism, no statistically significant changes from baseline values were observed in parathormone, alkaline phosphatase, calcitonin, urinary calcium/creatinine ratio, and bone mineral content expressed by the bone density.
authors.affiliation: Patologia Ginecologica ed Ostetrica e Puericultura Prenatale, University of Padova, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Marchesoni
authors.forename: M
authors.initials: M
authors.lastname: Dal Pozzo
authors.forename: L
authors.initials: L
authors.lastname: Dal Magro
authors.forename: D M
authors.initials: DM
authors.lastname: Paternoster
authors.forename: E
authors.initials: E
authors.lastname: Ferroni
authors.forename: T
authors.initials: T
authors.lastname: Maggino
authors.forename: C
authors.initials: C
authors.lastname: Romagnolo
authors.forename: B
authors.initials: B
authors.lastname: Mozzanega
mesh_terms: D004092:20-alpha-Dihydroprogesterone / Q000008:administration & dosage*; D000279:Administration, Cutaneous; D001777:Blood Coagulation; D001794:Blood Pressure; D015992:Body Mass Index; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism; D004958:Estradiol / Q000008:administration & dosage*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D006801:Humans; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077563:Norethindrone Acetate
chemical_list: D008055:Lipids; D008074:Lipoproteins; D004092:20-alpha-Dihydroprogesterone; D004958:Estradiol; D000077563:Norethindrone Acetate; D009640:Norethindrone